140 related articles for article (PubMed ID: 30049379)
1. Mutation Ensemble for Response to Programmed Cell Death 1 Inhibition in Thymic Carcinoma.
Lee HS; Truong CY; Burt BM
J Thorac Oncol; 2018 Aug; 13(8):e150-e152. PubMed ID: 30049379
[No Abstract] [Full Text] [Related]
2. Molecular predictors of response to pembrolizumab in thymic carcinoma.
He Y; Ramesh A; Gusev Y; Bhuvaneshwar K; Giaccone G
Cell Rep Med; 2021 Sep; 2(9):100392. PubMed ID: 34622229
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis.
Chen HF; Wu LX; Li XF; Zhu YC; Pan WW; Wang WX; Xu CW; Huang JH; Wu MH; Du KQ
Tumori; 2020 Aug; 106(4):306-311. PubMed ID: 32366210
[TBL] [Abstract][Full Text] [Related]
4. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.
Buti S; Donini M; Sergio P; Garagnani L; Schirosi L; Passalacqua R; Rossi G
J Clin Oncol; 2011 Nov; 29(33):e803-5. PubMed ID: 21969494
[No Abstract] [Full Text] [Related]
5. Thymic malignancies: Twisting between autoimmunity and immunotherapy.
Girard N
Lung Cancer; 2017 Aug; 110():68-70. PubMed ID: 28526140
[No Abstract] [Full Text] [Related]
6. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Ströbel P; Hartmann M; Jakob A; Mikesch K; Brink I; Dirnhofer S; Marx A
N Engl J Med; 2004 Jun; 350(25):2625-6. PubMed ID: 15201427
[No Abstract] [Full Text] [Related]
7. When a thymic carcinoma "becomes" a GIST.
Rossi V; Donini M; Sergio P; Passalacqua R; Rossi G; Buti S
Lung Cancer; 2013 Apr; 80(1):106-8. PubMed ID: 23375402
[TBL] [Abstract][Full Text] [Related]
8. Successful pembrolizumab treatment for microsatellite instability-high thymoma: A case report.
Kaneko T; Sekine A; Komatsu S; Otoshi R; Haga S; Tagami Y; Kaneko T; Ogura T
Respir Investig; 2024 Jul; 62(4):517-519. PubMed ID: 38631274
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
[TBL] [Abstract][Full Text] [Related]
10. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.
Mammen AL; Rajan A; Pak K; Lehky T; Casciola-Rosen L; Donahue RN; Lepone LM; Zekeridou A; Pittock SJ; Hassan R; Schlom J; Gulley JL
Ann Rheum Dis; 2019 Jan; 78(1):150-152. PubMed ID: 30185415
[No Abstract] [Full Text] [Related]
11. Molecular aspects of thymic carcinoma.
Weissferdt A; Wistuba II; Moran CA
Lung Cancer; 2012 Nov; 78(2):127-32. PubMed ID: 22921473
[TBL] [Abstract][Full Text] [Related]
12. [Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].
Ströbel P; Knop S; Einsele H; Müller-Hermelink HK; Marx A
Verh Dtsch Ges Pathol; 2007; 91():177-86. PubMed ID: 18314613
[TBL] [Abstract][Full Text] [Related]
13. Response to Pembrolizumab in a Patient with Relapsing Thymoma.
Zander T; Aebi S; Rast AC; Zander A; Winterhalder R; Brand C; Diebold J; Gautschi O
J Thorac Oncol; 2016 Dec; 11(12):e147-e149. PubMed ID: 27498287
[No Abstract] [Full Text] [Related]
14. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.
Bisagni G; Rossi G; Cavazza A; Sartori G; Gardini G; Boni C
J Thorac Oncol; 2009 Jun; 4(6):773-5. PubMed ID: 19461405
[TBL] [Abstract][Full Text] [Related]
15. The phenotype of lymphocytes in a thymoma as studied with monoclonal antibodies.
Woda BA; Bain K; Vander Salm T
Clin Immunol Immunopathol; 1984 Feb; 30(2):197-201. PubMed ID: 6362939
[TBL] [Abstract][Full Text] [Related]
16. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.
Bellissimo T; Ganci F; Gallo E; Sacconi A; Tito C; De Angelis L; Pulito C; Masciarelli S; Diso D; Anile M; Petrozza V; Giangaspero F; Pescarmona E; Facciolo F; Venuta F; Marino M; Blandino G; Fazi F
Mol Cancer; 2017 May; 16(1):88. PubMed ID: 28486946
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for advanced thymic tumors.
Rajan A; Giaccone G
J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S361-4. PubMed ID: 20859134
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
19. Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma.
Hyun JW; Kim GS; Kim SH; Cho JY; Kim HJ; Lee GK; Kim HJ; Kwon SU
Clin Lung Cancer; 2020 Mar; 21(2):e74-e77. PubMed ID: 31718909
[No Abstract] [Full Text] [Related]
20. Response of thymoma to cetuximab.
Farina G; Garassino MC; Gambacorta M; La Verde N; Gherardi G; Scanni A
Lancet Oncol; 2007 May; 8(5):449-50. PubMed ID: 17466903
[No Abstract] [Full Text] [Related]
[Next] [New Search]
